Compile Data Set for Download or QSAR
maximum 50k data
Found 28 of ic50 for monomerid = 280739
TargetGlutamate receptor ionotropic, NMDA 2B(Homo sapiens (Human))
Rugen Holdings (Cayman)

US Patent
LigandPNGBDBM280739(US10030026, Compound LX-1 | US10221182, Compound L...)
Affinity DataIC50:  24nMAssay Description:HEK293 cell lines stably expressing cloned human NR1/NR2B and NR1/NR2A, respectively, were established according to standard previously described met...More data for this Ligand-Target Pair
In DepthDetails US Patent
TargetGlutamate receptor ionotropic, NMDA 2B(Homo sapiens (Human))
Rugen Holdings (Cayman)

US Patent
LigandPNGBDBM280739(US10030026, Compound LX-1 | US10221182, Compound L...)
Affinity DataIC50:  24nMAssay Description:HEK293 cell lines stably expressing cloned human NR1/NR2B and NR1/NR2A, respectively, were established according to standard previously described met...More data for this Ligand-Target Pair
In DepthDetails US Patent
TargetGlutamate receptor ionotropic, NMDA 2B(Homo sapiens (Human))
Rugen Holdings (Cayman)

US Patent
LigandPNGBDBM280739(US10030026, Compound LX-1 | US10221182, Compound L...)
Affinity DataIC50:  24nMT: 2°CAssay Description:HEK293 cell lines stably expressing cloned human NR1/NR2B and NR1/NR2A, respectively, were established according to standard previously described met...More data for this Ligand-Target Pair
In DepthDetails US Patent
TargetGlutamate receptor ionotropic, NMDA 2B(Homo sapiens (Human))
Rugen Holdings (Cayman)

US Patent
LigandPNGBDBM280739(US10030026, Compound LX-1 | US10221182, Compound L...)
Affinity DataIC50:  24nMAssay Description:HEK293 cell lines stably expressing cloned human NR1/NR2B and NR1/NR2A, respectively, were established according to standard previously described met...More data for this Ligand-Target Pair
In DepthDetails US Patent
TargetGlutamate receptor ionotropic, NMDA 2B(Homo sapiens (Human))
Rugen Holdings (Cayman)

US Patent
LigandPNGBDBM280739(US10030026, Compound LX-1 | US10221182, Compound L...)
Affinity DataIC50:  24nMAssay Description:HEK293 cell lines stably expressing cloned human NR1/NR2B and NR1/NR2A, respectively, were established according to standard previously described met...More data for this Ligand-Target Pair
In DepthDetails US Patent
TargetGlutamate receptor ionotropic, NMDA 2B(Homo sapiens (Human))
Rugen Holdings (Cayman)

US Patent
LigandPNGBDBM280739(US10030026, Compound LX-1 | US10221182, Compound L...)
Affinity DataIC50:  24nMMore data for this Ligand-Target Pair
In DepthDetails US Patent
TargetGlutamate receptor ionotropic, NMDA 2B(Homo sapiens (Human))
Rugen Holdings (Cayman)

US Patent
LigandPNGBDBM280739(US10030026, Compound LX-1 | US10221182, Compound L...)
Affinity DataIC50:  24nMAssay Description:HEK293 cell lines stably expressing cloned human NR1/NR2B and NR1/NR2A, respectively, were established according to standard previously described met...More data for this Ligand-Target Pair
In DepthDetails US Patent
TargetGlutamate receptor ionotropic, NMDA 2B(Homo sapiens (Human))
Rugen Holdings (Cayman)

US Patent
LigandPNGBDBM280739(US10030026, Compound LX-1 | US10221182, Compound L...)
Affinity DataIC50:  24nMpH: 7.35Assay Description:The assay was performed on hERG channel stably expressed in HEK293 cells. The cells were cultured at 37° C. in a humidified CO2 incubator in the grow...More data for this Ligand-Target Pair
In DepthDetails US Patent
TargetGlutamate receptor ionotropic, NMDA 2B(Homo sapiens (Human))
Rugen Holdings (Cayman)

US Patent
LigandPNGBDBM280739(US10030026, Compound LX-1 | US10221182, Compound L...)
Affinity DataIC50:  24nMMore data for this Ligand-Target Pair
In DepthDetails US Patent
TargetGlutamate receptor ionotropic, NMDA 2B(Homo sapiens (Human))
Rugen Holdings (Cayman)

US Patent
LigandPNGBDBM280739(US10030026, Compound LX-1 | US10221182, Compound L...)
Affinity DataIC50:  24nMT: 2°CAssay Description:HEK293 cell lines stably expressing cloned human NR1/NR2B and NR1/NR2A, respectively, were established according to standard previously described met...More data for this Ligand-Target Pair
In DepthDetails US Patent
TargetGlutamate receptor ionotropic, NMDA 2B(Homo sapiens (Human))
Rugen Holdings (Cayman)

US Patent
LigandPNGBDBM280739(US10030026, Compound LX-1 | US10221182, Compound L...)
Affinity DataIC50:  24nMAssay Description:HEK293 cell lines stably expressing cloned human NR1/NR2B and NR1/NR2A, respectively, were established according to standard previously described met...More data for this Ligand-Target Pair
In DepthDetails US Patent
TargetGlutamate receptor ionotropic, NMDA 2B(Homo sapiens (Human))
Rugen Holdings (Cayman)

US Patent
LigandPNGBDBM280739(US10030026, Compound LX-1 | US10221182, Compound L...)
Affinity DataIC50:  24nMMore data for this Ligand-Target Pair
In DepthDetails US Patent
TargetCytochrome P450 2D6(Homo sapiens (Human))
Rugen Holdings (Cayman)

US Patent
LigandPNGBDBM280739(US10030026, Compound LX-1 | US10221182, Compound L...)
Affinity DataIC50:  1.00E+3nMAssay Description:Inhibitory activities of test compounds on 5 major isoforms of CYP P450 were evaluated by using pooled human liver microsome (HLM, purchased from BD ...More data for this Ligand-Target Pair
In DepthDetails US Patent
TargetCytochrome P450 2D6(Homo sapiens (Human))
Rugen Holdings (Cayman)

US Patent
LigandPNGBDBM280739(US10030026, Compound LX-1 | US10221182, Compound L...)
Affinity DataIC50:  1.00E+3nMAssay Description:Inhibitory activities of test compounds on 5 major isoforms of CYP P450 were evaluated by using pooled human liver microsome (HLM, purchased from BD ...More data for this Ligand-Target Pair
In DepthDetails US Patent
TargetCytochrome P450 2D6(Homo sapiens (Human))
Rugen Holdings (Cayman)

US Patent
LigandPNGBDBM280739(US10030026, Compound LX-1 | US10221182, Compound L...)
Affinity DataIC50:  1.00E+3nMpH: 7.4Assay Description:Inhibitory activities of test compounds on 5 major isoforms of CYP P450 were evaluated by using pooled human liver microsome (HLM, purchased from BD ...More data for this Ligand-Target Pair
In DepthDetails US Patent
TargetPotassium voltage-gated channel subfamily H member 2(Homo sapiens (Human))
Rugen Holdings (Cayman)

US Patent
LigandPNGBDBM280739(US10030026, Compound LX-1 | US10221182, Compound L...)
Affinity DataIC50:  1.00E+3nMpH: 7.4Assay Description:Inhibitory activities of test compounds on 5 major isoforms of CYP P450 were evaluated by using pooled human liver microsome (HLM, purchased from BD ...More data for this Ligand-Target Pair
In DepthDetails US Patent
TargetCytochrome P450 2D6(Homo sapiens (Human))
Rugen Holdings (Cayman)

US Patent
LigandPNGBDBM280739(US10030026, Compound LX-1 | US10221182, Compound L...)
Affinity DataIC50:  1.00E+3nMAssay Description:Inhibitory activities of test compounds on 5 major isoforms of CYP P450 were evaluated by using pooled human liver microsome (HLM, purchased from BD ...More data for this Ligand-Target Pair
In DepthDetails US Patent
TargetCytochrome P450 2D6(Homo sapiens (Human))
Rugen Holdings (Cayman)

US Patent
LigandPNGBDBM280739(US10030026, Compound LX-1 | US10221182, Compound L...)
Affinity DataIC50:  1.00E+3nMAssay Description:Inhibitory activities of test compounds on 5 major isoforms of CYP P450 were evaluated by using pooled human liver microsome (HLM, purchased from BD ...More data for this Ligand-Target Pair
In DepthDetails US Patent
TargetCytochrome P450 2D6(Homo sapiens (Human))
Rugen Holdings (Cayman)

US Patent
LigandPNGBDBM280739(US10030026, Compound LX-1 | US10221182, Compound L...)
Affinity DataIC50:  1.00E+3nMAssay Description:CYP P450: Inhibitory activities of test compounds on 5 major isoforms of CYP P450 were evaluated by using pooled human liver microsome (HLM, purchase...More data for this Ligand-Target Pair
In DepthDetails US Patent
TargetCytochrome P450 2D6(Homo sapiens (Human))
Rugen Holdings (Cayman)

US Patent
LigandPNGBDBM280739(US10030026, Compound LX-1 | US10221182, Compound L...)
Affinity DataIC50:  1.00E+3nMAssay Description:Inhibitory activities of test compounds on 5 major isoforms of CYP P450 were evaluated by using pooled human liver microsome (HLM, purchased from BD ...More data for this Ligand-Target Pair
In DepthDetails US Patent
TargetPotassium voltage-gated channel subfamily H member 2(Homo sapiens (Human))
Rugen Holdings (Cayman)

US Patent
LigandPNGBDBM280739(US10030026, Compound LX-1 | US10221182, Compound L...)
Affinity DataIC50:  4.50E+3nMAssay Description:The assay was performed on hERG channel stably expressed in HEK293 cells. The cells were cultured at 37° C. in a humidified CO2 incubator in the grow...More data for this Ligand-Target Pair
In DepthDetails US Patent
TargetPotassium voltage-gated channel subfamily H member 2(Homo sapiens (Human))
Rugen Holdings (Cayman)

US Patent
LigandPNGBDBM280739(US10030026, Compound LX-1 | US10221182, Compound L...)
Affinity DataIC50:  4.50E+3nMAssay Description:The assay was performed on hERG channel stably expressed in HEK293 cells. The cells were cultured at 37° C. in a humidified CO2 incubator in the grow...More data for this Ligand-Target Pair
In DepthDetails US Patent
TargetPotassium voltage-gated channel subfamily H member 2(Homo sapiens (Human))
Rugen Holdings (Cayman)

US Patent
LigandPNGBDBM280739(US10030026, Compound LX-1 | US10221182, Compound L...)
Affinity DataIC50:  4.50E+3nMAssay Description:The assay was performed on hERG channel stably expressed in HEK293 cells. The cells were cultured at 37° C. in a humidified CO2 incubator in the grow...More data for this Ligand-Target Pair
In DepthDetails US Patent
TargetPotassium voltage-gated channel subfamily H member 2(Homo sapiens (Human))
Rugen Holdings (Cayman)

US Patent
LigandPNGBDBM280739(US10030026, Compound LX-1 | US10221182, Compound L...)
Affinity DataIC50:  4.50E+3nMpH: 7.35Assay Description:The assay was performed on hERG channel stably expressed in HEK293 cells. The cells were cultured at 37° C. in a humidified CO2 incubator in the grow...More data for this Ligand-Target Pair
In DepthDetails US Patent
TargetPotassium voltage-gated channel subfamily H member 2(Homo sapiens (Human))
Rugen Holdings (Cayman)

US Patent
LigandPNGBDBM280739(US10030026, Compound LX-1 | US10221182, Compound L...)
Affinity DataIC50:  4.50E+3nMAssay Description:The assay was performed on hERG channel stably expressed in HEK293 cells. The cells were cultured at 37° C. in a humidified CO2 incubator in the grow...More data for this Ligand-Target Pair
In DepthDetails US Patent
TargetPotassium voltage-gated channel subfamily H member 2(Homo sapiens (Human))
Rugen Holdings (Cayman)

US Patent
LigandPNGBDBM280739(US10030026, Compound LX-1 | US10221182, Compound L...)
Affinity DataIC50:  4.50E+3nMAssay Description:hERG: The assay was performed on hERG channel stably expressed in HEK293 cells. The cells were cultured at 37° C. in a humidified CO2 incubator in th...More data for this Ligand-Target Pair
In DepthDetails US Patent
TargetPotassium voltage-gated channel subfamily H member 2(Homo sapiens (Human))
Rugen Holdings (Cayman)

US Patent
LigandPNGBDBM280739(US10030026, Compound LX-1 | US10221182, Compound L...)
Affinity DataIC50:  4.50E+3nMpH: 7.35Assay Description:The assay was performed on hERG channel stably expressed in HEK293 cells. The cells were cultured at 37° C. in a humidified CO2 incubator in the grow...More data for this Ligand-Target Pair
In DepthDetails US Patent
TargetPotassium voltage-gated channel subfamily H member 2(Homo sapiens (Human))
Rugen Holdings (Cayman)

US Patent
LigandPNGBDBM280739(US10030026, Compound LX-1 | US10221182, Compound L...)
Affinity DataIC50:  4.50E+3nMAssay Description:The assay was performed on hERG channel stably expressed in HEK293 cells. The cells were cultured at 37° C. in a humidified CO2 incubator in the grow...More data for this Ligand-Target Pair
In DepthDetails US Patent